Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU

EMA Questions Efficacy Of Eye Drop

29 Jun 2020

A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.

Eyebrows that were raised when Novartis AG splashed out $3.4bn upfront to buy Xiidra from Takeda Pharmaceutical Co. Ltd. are now twitching wildly after the Swiss major withdrew its filing for the dry eye disease drug in Europe and regulators raised concerns about its efficacy.

Last July, Novartis agreed to pay the huge upfront, plus potential milestone payments of up to $1.9bn, for Xiidra (lifitegrast),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

11 Jun 2025

• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

27 May 2025

• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.